---
title: Migraine Inducing Effects and Changes in Brain Haemodynamics of PGI2
nct_id: NCT00510172
overall_status: UNKNOWN
phase: NA
sponsor: Glostrup University Hospital, Copenhagen
study_type: INTERVENTIONAL
primary_condition: Headache
countries: Denmark
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00510172.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00510172"
ct_last_update_post_date: 2007-08-01
last_seen_at: "2026-05-12T07:12:54.113Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Migraine Inducing Effects and Changes in Brain Haemodynamics of PGI2

**NCT ID:** [NCT00510172](https://clinicaltrials.gov/study/NCT00510172)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 12
- **Lead Sponsor:** Glostrup University Hospital, Copenhagen
- **Conditions:** Headache, Migraine, Vasodilatation
- **Start Date:** 2006-12
- **Completion Date:** 2007-09
- **CT.gov Last Update:** 2007-08-01

## Brief Summary

We hypothesised that intravenous infusion of PGI2 induced headache or migraine and cranial vasodilatation in migraineurs.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 55 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* migraine without aura and healthy apart from that
* age 18-55 years
* 50-100 kg
* Secure contraceptives

Exclusion Criteria:

* Tension Type Headache more than 3 time a month
* Other primary headaches
* Medication prior to the study (closer than 4 times plasma halflife)
* Migraine or headache 5 days prior to study.
* Hypertension (systolic BP \>150 mmHg and/or diastolic BP \>100 mmHg).
* Hypotension (systolic BP \<90 mmHg and/or diastolic BP \<50 mmHg).
* Heart-vessel disease of any kind incl cerebrovascular disease.
* Anamnestic or clinical signs of psychiatric disease or abuse.
* Anamnestic or clinical signs of disease of any kind relevant for participation in the study.
```

## Arms

- **1** (ACTIVE_COMPARATOR) — Active treatment
- **2** (PLACEBO_COMPARATOR) — Placebo

## Interventions

- **Prostacyclin, PGI2** (DRUG) — 10 ng/kg/min of epoprostenol (stable PGI2)
- **Placebo** (DRUG) — NaCL 0,9%

## Primary Outcomes

- **Headache and accompanying symptoms. Blood flow velocity in the middle cerebral artery, diameter changes in superficial temporal artery and radial artery.** _(time frame: 14 hours)_

## Secondary Outcomes

- **Blood pressure, pulse** _(time frame: 100 min)_

## Locations (1)

- Danish Headache Center, Copenhagen, Glostrup, Denmark — _RECRUITING_

## Recent Field Changes (last 30 days)

- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.danish headache center|copenhagen|glostrup|denmark` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00510172.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00510172*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*